ArticleMolecular pain2010
Ablation of rat TRPV1-expressing Adelta/C-fibers with resiniferatoxin: analysis of withdrawal behaviors, recovery of function and molecular correlates.
Article in Molecular pain, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06030297 (Diode Laser as a Biomarker for Neuropathic Pain of Peripheral Origin.), which is not on this map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Diode Laser as a Biomarker for Neuropathic Pain of Peripheral Origin.
Who cites it
54 citing papers in PubMed, 80 citations in OpenAlex.
- Characterization of Patients With and Without Painful Peripheral Neuropathy After Receiving Neurotoxic Chemotherapy: Traditional Quantitative Sensory Testing vs C-Fiber and Aδ-Fiber Selective Diode Laser Stimulation.The journal of pain · 2022Trial
- Nociceptor-enriched CAPS1 isoform couples to CabioRxiv : the preprint server for biology · 2026Article
- Small peptides derived from the autoinhibitory XY linker of phospholipase C-β isoforms inhibit enzyme activity and reduce inflammation.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2026Article
- Article
- CGRP signaling links tumor-associated pain to immune evasion in oral squamous cell carcinoma.Cell reports · 2026Article
- Artificial Photothermal Nociceptor Using Mott Oscillators.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Mirtazapine Improves Locomotor Activity and Attenuates Neuropathic Pain Following Spinal Cord Injury in Rats via Neuroinflammation Modulation.Neurochemical research · 2024Article
- Histochemical analysis of the biphasic properties of formalin pain-induced behavior.Biochemistry and biophysics reports · 2023Article
- Recent Progress in Gels for Neuropathic Pain.Gels (Basel, Switzerland) · 2023Review
- Article
- The Role of Saponins in the Treatment of Neuropathic Pain.Molecules (Basel, Switzerland) · 2022Review
- Anatomical Analysis of Transient Potential Vanilloid Receptor 1 (Frontiers in molecular neuroscience · 2022Article
- Article
- A re-innervatedSkin health and disease · 2021Article
- Article
- Molecular Pathways Linking Oxylipins to Nociception in Rats.The journal of pain · 2021Article
- Transcriptomic Classification of Neurons Innervating Teeth.Journal of dental research · 2020Article
- The capsaicin receptor TRPV1 is the first line defense protecting from acute non damaging heat: a translational approach.Journal of translational medicine · 2020Article
- Neuroimmune System as a Driving Force for Plasticity Following CNS Injury.Frontiers in cellular neuroscience · 2020Review
- The Mysteries of Capsaicin-Sensitive Afferents.Frontiers in physiology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundAblation of TRPV1-expressing nociceptive fibers with the potent capsaicin analog resiniferatoxin (RTX) results in long lasting pain relief. RTX is particularly adaptable to focal application, and the induced chemical axonopathy leads to analgesia with a duration that is influenced by dose, route of administration, and the rate of fiber regeneration. TRPV1 is expressed in a subpopulation of unmyelinated C- and lightly myelinated Adelta fibers that detect changes in skin temperature at low and high rates of noxious heating, respectively. Here we investigate fiber-type specific behaviors, their time course of recovery and molecular correlates of axon damage and nociception using infrared laser stimuli following an RTX-induced peripheral axonopathy.
resultsRTX was injected into rat hind paws (mid-plantar) to produce thermal hypoalgesia. An infrared diode laser was used to stimulate Adelta fibers in the paw with a small-diameter (1.6 mm), high-energy, 100 msec pulse, or C-fibers with a wide-diameter (5 mm), long-duration, low-energy pulse. We monitored behavioral responses to indicate loss and regeneration of fibers. At the site of injection, responses to C-fiber stimuli were significantly attenuated for two weeks after 5 or 50 ng RTX. Responses to Adelta stimuli were significantly attenuated for two weeks at the highest intensity stimulus, and for 5 weeks to a less intense Adelta stimulus. Stimulation on the toe, a site distal to the injection, showed significant attenuation of Adelta responses for 7- 8 weeks after 5 ng, or 9-10 weeks after 50 ng RTX. In contrast, responses to C-fiber stimuli exhibited basically normal responses at 5 weeks after RTX. During the period of fiber loss and recovery, molecular markers for nerve regeneration (ATF3 and galanin) are upregulated in the dorsal root ganglia (DRG) when behavior is maximally attenuated, but markers of nociceptive activity (c-Fos in spinal cord and MCP-1 in DRG), although induced immediately after RTX treatment, returned to normal.
conclusionBehavioral recovery following peripheral RTX treatment is linked to regeneration of TRPV1-expressing Adelta and C-fibers and sustained expression of molecular markers. Infrared laser stimulation is a potentially valuable tool for evaluating the behavioral role of Adelta fibers in pain and pain control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.